<code id='7F3A32565E'></code><style id='7F3A32565E'></style>
    • <acronym id='7F3A32565E'></acronym>
      <center id='7F3A32565E'><center id='7F3A32565E'><tfoot id='7F3A32565E'></tfoot></center><abbr id='7F3A32565E'><dir id='7F3A32565E'><tfoot id='7F3A32565E'></tfoot><noframes id='7F3A32565E'>

    • <optgroup id='7F3A32565E'><strike id='7F3A32565E'><sup id='7F3A32565E'></sup></strike><code id='7F3A32565E'></code></optgroup>
        1. <b id='7F3A32565E'><label id='7F3A32565E'><select id='7F3A32565E'><dt id='7F3A32565E'><span id='7F3A32565E'></span></dt></select></label></b><u id='7F3A32565E'></u>
          <i id='7F3A32565E'><strike id='7F3A32565E'><tt id='7F3A32565E'><pre id='7F3A32565E'></pre></tt></strike></i>

          hotspot

          hotspot

          author:entertainment    Page View:326
          J.P. Morgan office building at night -- JPM health business coverage from STAT
          Adobe

          SAN FRANCISCO — Almost three years ago, the country’s biggest bank unveiled a lofty plan to fix the health care industry’s entrenched problems. It broke off $250 million to stand up a new business unit, Morgan Health, to do so. 

          Today, Morgan Health’s CEO, Dan Mendelson, aided by a newly hired flack, emailed reporters attending that bank’s annual investor confab, the J.P. Morgan Healthcare Conference, asking them for interviews. For the uninitiated, it’s usually the other way around.

          advertisement

          Their message? We’re still here. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Readout Newsletter: Illumina, CRISPR, Regeneron
          Readout Newsletter: Illumina, CRISPR, Regeneron

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Vaccine advisory panel ACIP left half staffed by HHS

          ACIP,normallya15-memberpanel,haseightvacancies,andfourmorecomingsoon.Whyhasn'tHHSsignedoffontheCDC's